Watson and Natco sign a licensing deal for a generic Revlimid

12/7/2010 | Bloomberg Businessweek

Natco Pharma granted Watson Pharmaceuticals domestic development and marketing rights to lenalidomide, a generic version of Celgene's multiple myeloma treatment Revlimid. The agreement entitles Watson to a share of sales profit. Natco is expected to be the first company to file for approval of a generic Revlimid.

View Full Article in:

Bloomberg Businessweek

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
President/Chief Executive Officer
MedCost
Winston-Salem, NC
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA
Director, Payer Marketing
Avalere Health
Washington, DC
Actuary
Meridian Health Plan
Detroit, MI
Chief Medical Officer, Texas Children's Health Plan
Cejka Executive Search for Texas Childre's Health Plan
Houston, TX